New Data At ESC Congress 2021 Shows Repatha® (evolocumab) Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome (ACS)
Heart attacks are often the result of vulnerable plaque ruptures.1,2,3,4,5 Key features of vulnerable plaques are a large lipid core with a thin fibrous cap that serves as a wall or barrier around the plaque to keep it intact.6 The HUYGENS study assessed…
